Literature DB >> 17300920

An intervention programme for the management of multidrug-resistant tuberculosis in France.

Marie-Laure Uffredi1, Chantal Truffot-Pernot, Bertrand Dautzenberg, Muriel Renard, Vincent Jarlier, Jérôme Robert.   

Abstract

As shown in a previous study, the outcome of multidrug-resistant tuberculosis (MDR-TB) in France is not satisfactory (41% success rate). To improve the management and outcome of patients with MDR-TB, a prospective intervention study was carried out in 1998-1999 by National Reference Centre (NRC) staff. NRC staff contacted (i) the microbiologists reporting MDR-TB patients in order to offer second-line drug testing and (ii) physicians to help tailor treatment regimens based on World Health Organization guidelines. A total of 45 MDR-TB patients were followed, including 33 for whom NRC staff successfully interacted with the physicians in charge and 12 patients managed without NRC collaboration. The crude proportion of favourable outcomes was 58%, and this proportion reached 70% for patients managed in collaboration with the NRC. Among the latter 33 patients, 32 were treated with at least three active drugs for a median duration of 12 months. In multivariate analysis, HIV-positive status was associated with treatment failure (hazard ratio (HR) 4.3), whereas NRC intervention was associated with a favourable outcome (HR 0.2). However, even in the NRC intervention group the median duration of treatment was shorter than planned (median 12 months) and 12% of patients were lost to follow-up. This intervention study provides encouraging results and should be continued until reference teams and a directly observed treatment strategy (DOTS) are implemented to improve patient management further.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17300920     DOI: 10.1016/j.ijantimicag.2006.11.023

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

1.  Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.

Authors:  L Guglielmetti; C Hewison; Z Avaliani; J Hughes; N Kiria; N Lomtadze; N Ndjeka; S Setkina; A Shabangu; W Sikhondze; A Skrahina; N Veziris; J Furin
Journal:  Int J Tuberc Lung Dis       Date:  2017-02-01       Impact factor: 2.373

2.  A close-up on the epidemiology and transmission of multidrug-resistant tuberculosis in Poland.

Authors:  T Jagielski; A Brzostek; A van Belkum; J Dziadek; E Augustynowicz-Kopeć; Z Zwolska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-20       Impact factor: 3.267

3.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.

Authors:  Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies
Journal:  Eur Respir J       Date:  2012-10-25       Impact factor: 16.671

Review 4.  A systematic review of the effectiveness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis.

Authors:  Amal Bassili; Christopher Fitzpatrick; Ejaz Qadeer; Razia Fatima; Katherine Floyd; Ernesto Jaramillo
Journal:  Am J Trop Med Hyg       Date:  2013-08       Impact factor: 2.345

5.  Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?

Authors:  Bayram Kiran; Tulin Cagatay; Philip Clark; Filiz Kosar; Penbe Cagatay; Sibel Yurt; Faruk Suzergoz; Ali Osman Gurol
Journal:  Arch Med Sci       Date:  2010-03-09       Impact factor: 3.318

6.  Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis.

Authors:  Vanina Meyssonnier; Thuy Van Bui; Nicolas Veziris; Vincent Jarlier; Jérôme Robert
Journal:  BMC Infect Dis       Date:  2014-01-10       Impact factor: 3.090

Review 7.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

8.  Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Authors:  Mayara L Bastos; Hamidah Hussain; Karin Weyer; Lourdes Garcia-Garcia; Vaira Leimane; Chi Chiu Leung; Masahiro Narita; Jose M Penã; Alfredo Ponce-de-Leon; Kwonjune J Seung; Karen Shean; José Sifuentes-Osornio; Martie Van der Walt; Tjip S Van der Werf; Wing Wai Yew; Dick Menzies
Journal:  Clin Infect Dis       Date:  2014-08-05       Impact factor: 9.079

9.  Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.

Authors:  Shama D Ahuja; David Ashkin; Monika Avendano; Rita Banerjee; Melissa Bauer; Jamie N Bayona; Mercedes C Becerra; Andrea Benedetti; Marcos Burgos; Rosella Centis; Eward D Chan; Chen-Yuan Chiang; Helen Cox; Lia D'Ambrosio; Kathy DeRiemer; Nguyen Huy Dung; Donald Enarson; Dennis Falzon; Katherine Flanagan; Jennifer Flood; Maria L Garcia-Garcia; Neel Gandhi; Reuben M Granich; Maria G Hollm-Delgado; Timothy H Holtz; Michael D Iseman; Leah G Jarlsberg; Salmaan Keshavjee; Hye-Ryoun Kim; Won-Jung Koh; Joey Lancaster; Christophe Lange; Wiel C M de Lange; Vaira Leimane; Chi Chiu Leung; Jiehui Li; Dick Menzies; Giovanni B Migliori; Sergey P Mishustin; Carole D Mitnick; Masa Narita; Philly O'Riordan; Madhukar Pai; Domingo Palmero; Seung-kyu Park; Geoffrey Pasvol; Jose Peña; Carlos Pérez-Guzmán; Maria I D Quelapio; Alfredo Ponce-de-Leon; Vija Riekstina; Jerome Robert; Sarah Royce; H Simon Schaaf; Kwonjune J Seung; Lena Shah; Tae Sun Shim; Sonya S Shin; Yuji Shiraishi; José Sifuentes-Osornio; Giovanni Sotgiu; Matthew J Strand; Payam Tabarsi; Thelma E Tupasi; Robert van Altena; Martie Van der Walt; Tjip S Van der Werf; Mario H Vargas; Pirett Viiklepp; Janice Westenhouse; Wing Wai Yew; Jae-Joon Yim
Journal:  PLoS Med       Date:  2012-08-28       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.